Search

Your search keyword '"Ahluwalia, Rohan"' showing total 9 results
Start Over Author "Ahluwalia, Rohan"
9 results on '"Ahluwalia, Rohan"'

2. Bayesian structural time series for biomedical sensor data: A flexible modeling framework for evaluating interventions

Author

Liu, Jason, primary, Spakowicz, Daniel J., additional, Ash, Garrett I., additional, Hoyd, Rebecca, additional, Ahluwalia, Rohan, additional, Zhang, Andrew, additional, Lou, Shaoke, additional, Lee, Donghoon, additional, Zhang, Jing, additional, Presley, Carolyn, additional, Greene, Ann, additional, Stults-Kolehmainen, Matthew, additional, Nally, Laura M., additional, Baker, Julien S., additional, Fucito, Lisa M., additional, Weinzimer, Stuart A., additional, Papachristos, Andrew V., additional, and Gerstein, Mark, additional

Published
2021
Full Text
View/download PDF

7. The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide

Author

Wang, Tzu-Fei, primary, Ahluwalia, Rohan, additional, Fiala, Mark A., additional, Trinkaus, Kathryn M., additional, Cox, Doug P., additional, Jaenicke, Matthew, additional, Moliske, Caitlin C., additional, Carson, Kenneth R., additional, Wildes, Tanya M., additional, Tomasson, Michael H., additional, Stockerl-Goldstein, Keith E., additional, and Vij, Ravi, additional

Published
2013
Full Text
View/download PDF

8. The Demographics and Outcomes of Patients with Multiple Myeloma Dual Refractory to or Intolerant of Bortezomib and Lenalidomide in the Era of Carfilzomib and Pomalidomide

Author

Wang, Tzu-Fei, primary, Fiala, Mark, additional, Ahluwalia, Rohan, additional, Trinkaus, Kathryn, additional, Moliske, Caitlin, additional, Cox, Doug, additional, Jaenicke, Matthew, additional, Stockerl-Goldstein, Keith, additional, Wildes, Tanya, additional, Carson, Kenneth R., additional, Tomasson, Michael H., additional, and Vij, Ravi, additional

Published
2012
Full Text
View/download PDF

9. The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.

Author

Wang, Tzu-Fei, Ahluwalia, Rohan, Fiala, Mark A., Trinkaus, Kathryn M., Cox, Doug P., Jaenicke, Matthew, Moliske, Caitlin C., Carson, Kenneth R., Wildes, Tanya M., Tomasson, Michael H., Stockerl-Goldstein, Keith E., and Vij, Ravi

Subjects
*MULTIPLE myeloma, *BORTEZOMIB, *RETROSPECTIVE studies, *WILCOXON signed-rank test, *RANDOMIZED controlled trials, *PROTEASOME inhibitors, *KAPLAN-Meier estimator
Abstract

Patients with multiple myeloma who are refractory or intolerant to both bortezomib and lenalidomide have a poor prognosis. Next-generation therapies carfilzomib and pomalidomide have shown promising activity in this dual refractory population. Here we describe the clinical characteristics and ascertain the effects of carfilzomib and pomalidomide on survival in this patient cohort. We retrospectively reviewed the records of 65 patients with dual refractory/intolerant myeloma diagnosed between January 2007 and May 2012 at a single institution. The median overall survival (OS) from the time patients became dual refractory/intolerant was 10.2 months. Patients who received carfilzomib or pomalidomide after they became dual refractory/intolerant had a better OS compared to those who did not (12.6 vs. 6.8 months, p = 0.03 by Wilcoxon test). Prospective randomized control trials are needed for confirmation. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results